17209
2017
eng
1589-1597
6
7
article
1
2018-11-19
--
--
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma
C-X-C-motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. We have recently reported promising first-in-man experience with CXCR4-directed endoradiotherapy (ERT) in multiple myeloma (MM).
Eight heavily pretreated MM patients underwent a total of 10 ERT cycles (7 patients with 1 cycle and a single patient with 3 cycles). ERT was administered in combination with chemotherapy and autologous stem cell support. End points were occurrence and timing of adverse events, progression-free and overall survival.
ERT was overall well tolerated without any unexpected acute adverse events or changes in vital signs. With absorbed tumor doses >30-70 Gy in intra- or extramedullary lesions, significant anti-myeloma activity was observed with 1 patient achieving complete remission and 5/8 partial remission. Directly after ERT major infectious complications were seen in one patient who died from sepsis 22 days after ERT, another patient with high tumor burden experienced lethal tumor lysis syndrome. Median progression-free survival was 54 days (range, 13-175), median overall survival was 223 days (range, 13-313). During follow-up (6 patients available), one patient died from infectious complications, 2/8 from disease progression, the remaining 3/8 patients are still alive.
CXCR4-directed ERT was well-tolerated and exerted anti-myeloma activity even at very advanced stage MM with presence of extramedullary disease. Further assessment of this novel treatment option is highly warranted.
Theranostics
10.7150/thno.19050
28529638
urn:nbn:de:bvb:20-opus-172095
Theranostics (2017) 7:6, pp. 1589-1597. https://www.thno.org/v07p1589.htm
true
true
CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International
Constantin Lapa
Ken Herrmann
Andreas Schirbel
Heribert Hänscheid
Katharina Lückerath
Margret Schottelius
Malte Kircher
Rudolf A. Werner
Martin Schreder
Samuel Samnick
Saskia Kropf
Stefan Knop
Andreas K. Buck
Hermann Einsele
Hans-Juergen Wester
K. Martin Kortüm
eng
uncontrolled
medicine
eng
uncontrolled
multiple myeloma
eng
uncontrolled
PET
eng
uncontrolled
CXCR4
eng
uncontrolled
theranostics
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17209/Lapa_v07p1589.pdf
32454
2022
eng
4133-4144
12
49
article
1
--
--
--
CXCR4-targeted theranostics in oncology
A growing body of literature reports on the upregulation of C-X-C motif chemokine receptor 4 (CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for molecular imaging and endoradiotherapy in a theranostic setting. For instance, the CXCR4-targeting positron emission tomography (PET) agent [\(^{68}\)Ga]PentixaFor has been proven useful for a comprehensive assessment of the current status quo of solid tumors, including adrenocortical carcinoma or small-cell lung cancer. In addition, [\(^{68}\)Ga]PentixaFor has also provided an excellent readout for hematological malignancies, such as multiple myeloma, marginal zone lymphoma, or mantle cell lymphoma. PET-based quantification of the CXCR4 capacities in vivo allows for selecting candidates that would be suitable for treatment using the theranostic equivalent [\(^{177}\)Lu]/[\(^{90}\)Y]PentixaTher. This CXCR4-directed theranostic concept has been used as a conditioning regimen prior to hematopoietic stem cell transplantation and to achieve sufficient anti-lymphoma/-tumor activity in particular for malignant tissues that are highly sensitive to radiation, such as the hematological system. Increasing the safety margin, pretherapeutic dosimetry is routinely performed to determine the optimal activity to enhance therapeutic efficacy and to reduce off-target adverse events. The present review will provide an overview of current applications for CXCR4-directed molecular imaging and will introduce the CXCR4-targeted theranostic concept for advanced hematological malignancies.
European Journal of Nuclear Medicine and Molecular Imaging
10.1007/s00259-022-05849-y
urn:nbn:de:bvb:20-opus-324545
@articleBuck.2022, author = Buck, Andreas K. and Serfling, Sebastian E. and Lindner, Thomas and Hänscheid, Heribert and Schirbel, Andreas and Hahner, Stefanie and Fassnacht, Martin and Einsele, Hermann and Werner, Rudolf A., year = 2022, title = CXCR4-targeted theranostics in oncology, pages = 4133–4144, volume = 49, number = 12, journal = European journal of nuclear medicine and molecular imaging, doi = 10.1007/s00259-022-05849-y
md5:2ba78eea50e4b235dc34d08ecd11ee84
2023-08-12T10:37:25+00:00
/tmp/phpKtPjJc
bibtex
64d760e520e2f0.54800151
European Journal of Nuclear Medicine and Molecular Imaging (2022) 49:12, 4133-4144. DOI: 10.1007/s00259-022-05849-y
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Andreas K. Buck
Sebastian E. Serfling
Thomas Lindner
Heribert Hänscheid
Andreas Schirbel
Stefanie Hahner
Martin Fassnacht
Hermann Einsele
Rudolf A. Werner
eng
uncontrolled
CXCR4
eng
uncontrolled
theranostics
eng
uncontrolled
C-X-C motif chemokine receptor 4
eng
uncontrolled
[68Ga]PentixaFor
eng
uncontrolled
[177Lu]PentixaTher
eng
uncontrolled
[90Y]PentixaTher
eng
uncontrolled
endoradiotherapy
eng
uncontrolled
adrenocortical carcinoma
eng
uncontrolled
multiple myeloma
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik I
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/32454/s00259-022-05849-y.pdf
19911
2012
eng
34-39
1
34
article
1
--
2012-08-17
--
Experimental first-pass method for testing and comparing sorbent polymers used in the clearance of iodine contrast materials
Background: Sorbents have been shown to adsorb iodinated radiocontrast media. Objective: In this study we describe a simple method to compare various sorbents in terms of capacity to adsorb radiocontrast media. Methods: Iodixanol solution was injected into columns filled with three types of sorbent at filtration velocities of increasing magnitude. Two variables of interest – contrast removal rate and matched iodine retention (MIR) – were calculated to measure the adsorption efficiency and the mass of contrast iodine adsorbed versus sorbent used, respectively. Results: The highest contrast removal and MIR for Porapak Q, CST 401 and Amberlite XAD4 were 41, 38 and 16% (p = 0.22 and 0.0005 for comparisons between Porapak Q-CST 401 and CST 401-Amberlite XAD4) and 0.060, 0.055 and 0.024, respectively (p = 0.18 and 0.0008). Extrapolation to a clinical scenario may suggest that removal of 8 ml iodixanol could be achieved by masses of sorbents of 43, 47 and 107 g, respectively. Conclusion: In this study we set a benchmark for comparing the radiocontrast-adsorbing efficiency of polymer sorbents during first-pass experiments, using a readily available methodology.
Blood Purification
0253-5068
1421-9735
10.1159/000339816
22907199
urn:nbn:de:bvb:20-opus-199118
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
swordwue
2020-01-28T13:23:19+00:00
attachment; filename=deposit.zip
fead639840be294616b8ab18cae04f1d
Blood Purification (2021) 34:1, 34-39. DOI: 10.1159/000339816
false
true
Deutsches Urheberrecht
George O. Angheloiu
Heribert Hänscheid
Xiaoyan Wen
Vincent Capponi
William D. Anderson
John A. Kellum
eng
uncontrolled
adsorption
eng
uncontrolled
acute renal failure
eng
uncontrolled
sorbents
eng
uncontrolled
iodine contrast
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Import
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/19911/BPU339816.pdf
17028
2018
eng
1-9
article
1
2018-10-27
--
--
Impact of Tumor Burden on Quantitative [\(^{68}\)Ga]DOTATOC Biodistribution
Purpose: As has been previously reported, the somatostatin receptor (SSTR) imaging agent [\(^{68}\)Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotate ([\(^{68}\)Ga]DOTATATE) demonstrates lower uptake in normal organs in patients with a high neuroendocrine tumor (NET) burden. Given the higher SSTR affinity of [\(^{68}\)Ga]DOTATATE, we aimed to quantitatively investigate the biodistribution of [\(^{68}\)Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ([68Ga]DOTATOC) to determine a potential correlation between uptake in normal organs and NET burden.
Procedures: Of the 44 included patients, 36/44 (82%) patients demonstrated suspicious radiotracer uptake on [\(^{68}\)Ga]DOTATOC positron emission tomography (PET)/x-ray computed tomography (CT). Volumes of Interest (VOIs) were defined for tumor lesions and normal organs (spleen, liver, kidneys, adrenals). Mean body weight corrected standardized uptake value (SUV\(_{mean}\)) for normal organs was assessed and was used to calculate the corresponding mean specific activity uptake (Upt: fraction of injected activity per kg of tissue). For the entire tumor burden, SUV\(_{mean}\), maximum standardized uptake value (SUV\(_{max}\)), and the total mass (TBM) was calculated and the decay corrected tumor fractional uptake (TBU) was assessed. A Spearman’s rank correlation coefficient was used to determine the correlations between normal organ uptake and tumor burden.
Results: The median SUV\(_{mean}\) was 18.7 for the spleen (kidneys, 9.2; adrenals, 6.8; liver, 5.6). For tumor burden, the median values were SUV\(_{mean}\) 6.9, SUV\(_{max}\) 35.5, TBM 42.6g, and TBU 1.2%. With increasing volume of distribution, represented by lean body mass and body surface area (BSA), Upt decreased in kidneys, liver, and adrenal glands and SUV\(_{mean}\) increased in the spleen. Correlation improved only for both kidneys and adrenals when the influence of the tumor uptake on the activity available for organ uptake was taken into account by the factor 1/(1-TBU). TBU was neither predictive for SUV\(_{mean}\) nor for Upt in any of the organs. The distribution of organ Upt vs. BSA/(1-TBU) were not different for patients with minor TBU (<3%) vs. higher TBU (>7%), indicating that the correlations observed in the present study are explainable by the body size effect. High tumor mass and uptake mitigated against G1 NET.
Conclusions: There is no significant impact on normal organ biodistribution with increasing tumor burden on [\(^{68}\)Ga]DOTATOC PET/CT. Potential implications include increased normal organ dose with [\(^{177}\)Lu-DOTA]\(^0\)-D-Phe\(^1\)-Tyr\(^3\)-Octreotide and decreased absolute lesion detection with [\(^{68}\)Ga]DOTATOC in high NET burden.
Molecular Imaging and Biology
urn:nbn:de:bvb:20-opus-170280
Johns Hopkins School of Medicine
Molecular Imaging and Biology (2018). https://doi.org/10.1007/s11307-018-1293-9
701983
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Rudolf Werner
Heribert Hänscheid
Jeffrey P. Leal
Mehrbod S. Javadi
Takahiro Higuchi
Martin A. Lodge
Andreas K. Buck
Martin G. Pomper
Constantin Lapa
Steven P. Rowe
eng
uncontrolled
somatostatin receptor
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
quantification
eng
uncontrolled
[68Ga]DOTATOC
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
SSTR-PET
eng
uncontrolled
theranostics
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17028/Rudolf_Werner_MIB_2018_ImpactOfTumorBurden.pdf
26547
2021
eng
2566-2572
8
48
article
1
--
--
--
Intraindividual comparison of [\(^{177}\)Lu]Lu-DOTA-EB-TATE and [\(^{177}\)Lu]Lu-DOTA-TOC
Purpose
The radiolabelled somatostatin analogue [\(^{177}\)Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [\(^{177}\)Lu]Lu-DOTA-TOC.
Methods
Activity kinetics in organs and tumours after [\(^{177}\)Lu]Lu-DOTA-EB-TATE and [\(^{177}\)Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy.
Resuluts
In comparison to [\(^{177}\)Lu]Lu-DOTA-TOC, tumour doses per administered activity were higher for [\(^{177}\)Lu]Lu-DOTA-EB-TATE in 4 of 5 patients (median ratio: 1.7; range: 0.9 to 3.9), kidney doses (median ratio: 3.2; range: 1.6 to 9.8) as well as spleen doses (median ratio: 4.7; range 1.2 to 6.2) in all patients, and liver doses in 3 of 4 evaluable patients (median ratio: 4.0; range: 0.7 to 4.9). The tumour to critical organs absorbed dose ratios were higher after [\(^{177}\)Lu]Lu-DOTA-TOC in 4 of 5 patients.
Conclusions
Prior to a treatment with [\(^{177}\)Lu]Lu-DOTA-EB-TATE, it should be assessed individually whether the compound is superior to established substances.
European Journal of Nuclear Medicine and Molecular Imaging
1619-7089
10.1007/s00259-020-05177-z
33452632
urn:nbn:de:bvb:20-opus-265470
publish
European Journal of Nuclear Medicine and Molecular Imaging 2021, 48(8):2566-2572. DOI: 10.1007/s00259-020-05177-z
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Heribert Hänscheid
Philipp E. Hartrampf
Andreas Schirbel
Andreas K. Buck
Constantin Lapa
eng
uncontrolled
intraindividual comparison
eng
uncontrolled
DOTA-EB-TATE
eng
uncontrolled
somatostatin receptor
eng
uncontrolled
evans blue
eng
uncontrolled
biokinetics
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/26547/Haenscheid_European.pdf
16116
2017
eng
247
No. Supplement 1
58
conferenceobject
Society of Nuclear Medicine and Molecular Imaging
1
2018-04-25
--
--
Less is sometimes more – Accurate Dose Mapping after Endoradiotherapy with \(^{177}\)Lu-DOTATATE/-TOC by One-Single Measurement after 96 h
No abstract available.
Journal of Nuclear Medicine
0161-5505
http://jnm.snmjournals.org/content/58/supplement_1/247.abstract
urn:nbn:de:bvb:20-opus-161168
This research was originally published in JNM. Werner R.A., Lapa C., Buck A.K., Lassmann M., Hänscheid H.Less is sometimes more – Accurate Dose Mapping after Endoradiotherapy with 177Lu-DOTATATE/-TOC by One-Single Measurement after 96 h. J Nucl Med May 1, 2017 vol. 58 no. supplement 1:247. © SNMMI
Johns Hopkins School of Medicine, Baltimore, MD, U.S.
701983
Journal of Nuclear Medicine May 1, 2017 vol. 58 no. supplement 1:247. © SNMMI.
Deutsches Urheberrecht
Rudolf Werner
Constantin Lapa
Andreas Buck
Michael Lassmann
Heribert Hänscheid
eng
uncontrolled
Neuroendocrine Tumor
eng
uncontrolled
theranostics
eng
uncontrolled
177Lu-DOTATATE
eng
uncontrolled
177Lu-DOTATOC
eng
uncontrolled
PRRT
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16116/Werner_Rudolf_Theranostics_Kongressbeitrag_accepted_version.pdf
15898
2018
eng
644–649
3
8
article
1
2018-03-14
--
--
Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.
Methods:
We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.
Results:
PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.
Conclusion:
Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.
Theranostics
10.7150/thno.22161
urn:nbn:de:bvb:20-opus-158983
Theranostics 2018, 8(3), 644-649. DOI: 10.7150/thno.22161
CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International
Constantin Lapa
Malte Kircher
Heribert Hänscheid
Andreas Schirbel
Götz Ulrich Grigoleit
Erdwine Klinker
Markus Böck
Samuel Samnick
Theo Pelzer
Andreas K Buck
eng
uncontrolled
peptide receptor
eng
uncontrolled
PRRT
eng
uncontrolled
sarcoidosis
eng
uncontrolled
somatostatin receptors
eng
uncontrolled
radionuclide therapy
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II)
Institut für Klinische Transfusionsmedizin und Hämotherapie
Förderzeitraum 2017
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/15898/Lapa_Theranostics.pdf
32443
2023
eng
1833-1834
6
50
article
1
--
--
--
Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
No abstract available.
European Journal of Nuclear Medicine and Molecular Imaging
10.1007/s00259-022-06061-8
urn:nbn:de:bvb:20-opus-324435
@articleWerner.2023, author = Werner, Rudolf A. and Sayehli, Cyrus and Hänscheid, Heribert and Higuchi, Takahiro and Serfling, Sebastian E. and Fassnacht, Martin and Goebeler, Maria-Elisabeth and Buck, Andreas K. and Kroiss, Matthias, year = 2023, title = Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma, pages = 1833–1834, volume = 50, number = 6, journal = European journal of nuclear medicine and molecular imaging, doi = 10.1007/s00259-022-06061-8
md5:7f5760f89c1db2356956d4f62a5db3cb
2023-08-12T10:19:33+00:00
/tmp/phpUZfgtd
bibtex
64d75cb5648f78.75399079
European Journal of Nuclear Medicine and Molecular Imaging (2023) 50:6, 1833-1834 DOI: 10.1007/s00259-022-06061-8
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Rudolf A. Werner
Cyrus Sayehli
Heribert Hänscheid
Takahiro Higuchi
Sebastian E. Serfling
Martin Fassnacht
Maria-Elisabeth Goebeler
Andreas K. Buck
Matthias Kroiss
eng
uncontrolled
papillary thyroid carcinoma (PTC)
eng
uncontrolled
selpercatinib
eng
uncontrolled
radioiodine
eng
uncontrolled
combination
eng
uncontrolled
thyroid carcinoma (TC)
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik I
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/32443/s00259-022-06061-8.pdf
17731
2016
eng
41233-41241
27
7
article
1
2019-02-26
--
--
The impact of \(^{177}\)Lu-octreotide therapy on \(^{99m}\)Tc-MAG3 clearance is not predictive for late nephropathy
Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of \(^{99m}\)Tc-mercaptoacetyltriglycine (\(^{99m}\)Tc-MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq \(^{177}\)Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p<0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-derived GFR estimates in predicting late nephropathy. TER assessed by \(^{99m}\)Tc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.
Oncotarget
10.18632/oncotarget.9775
urn:nbn:de:bvb:20-opus-177318
Oncotarget 2016, 7:27, 41233-41241. DOI: 10.18632/oncotarget.9775
false
true
Rudolf A. Werner
Seval Beykan
Takahiro Higuchi
Katharina Lückerath
Alexander Weich
Michael Scheurlen
Christina Bluemel
Ken Herrmann
Andreas K. Buck
Michael Lassmann
Constantin Lapa
Heribert Hänscheid
eng
uncontrolled
renal scintigraphy
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
177Lu
eng
uncontrolled
MAG3
eng
uncontrolled
PRRT
Pharmakologie, Therapeutik
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17731/Werner_Oncotarget.pdf